KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy

Autor: Thusharie Liyanage, Nimsha Liyanage, Lakmini Mudduwa, Suresh K. Rayala, Shania Gunasekara, Deepthika Abeysiriwardhana, Harshini Peiris
Rok vydání: 2018
Předmět:
0301 basic medicine
Oncology
Cytoplasm
Cancer Research
medicine.medical_treatment
Kaplan-Meier Estimate
Breast cancer
0302 clinical medicine
Surgical oncology
Breast
KIBRA
skin and connective tissue diseases
Tissue microarray
Recurrence free survival
Intracellular Signaling Peptides and Proteins
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Prognosis
Immunohistochemistry
Receptors
Estrogen
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Biomarker (medicine)
Female
Receptors
Progesterone
Research Article
Endocrine therapy
Adult
medicine.medical_specialty
Breast Neoplasms
lcsh:RC254-282
Disease-Free Survival
03 medical and health sciences
Internal medicine
Biomarkers
Tumor
Genetics
medicine
Adjuvant therapy
Humans
Retrospective Studies
Cell Nucleus
Chemotherapy
business.industry
Retrospective cohort study
Phosphoproteins
medicine.disease
Cross-Sectional Studies
030104 developmental biology
ER
Neoplasm Recurrence
Local
business
Zdroj: BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
ISSN: 1471-2407
DOI: 10.1186/s12885-018-4491-6
Popis: Background This study was carried out to evaluate the prognostic value of KIBRA in breast cancer. Methods This retrospective study included breast cancer patients who sought the services of the immunohistochemistry laboratory of our unit from 2006 to 2015. Tissue microarrays were constructed and immunohistochemical staining was done to assess the KIBRA expression. The Kaplan-Meier model for univariate and Cox-regression model with backward stepwise factor retention method for multivariate analyses were used. Chi square test was used to find out the associations with the established prognostic features. Results A total of 1124 patients were included in the study and KIBRA staining of 909 breast cancers were available for analysis. Cytoplasmic KIBRA expression was seen in 39.5% and nuclear expression in 44.8%. Overall KIBRA–low breast cancers accounted for 41.5%. KIBRA nuclear expression was significantly associated with positive ER and PR expression. Luminal breast cancer patients who had endocrine therapy and KIBRA-low expression had a RFS disadvantage over those who were positive for KIBRA (p = 0.02). Similarly, patients who received chemotherapy and had overall KIBRA-low expression also demonstrated a RFS disadvantage compared to those who had overall positive KIBRA expression (p = 0.018). This effect of KIBRA was independent of the other factors considered for the model. Conclusion Overall low-KIBRA expression has an independent effect on the RFS and predicts the RFS outcome of luminal breast cancer patients who received endocrine therapy and breast cancer patients who received chemotherapy.
Databáze: OpenAIRE
Externí odkaz: